Aprobado por la FDA el fármaco Orzeyful (oveporexton), un agonista del receptor de orexina 2 (OX2R), para tratar la narcolepsia tipo 1.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms?utm_medium=email&_hsenc=p2ANqtz-8xYF4Dj9qJjUHaI8XqS1OAbplSQNRLz_574_nb7USrOV4MPh5WNkFJAPFJlbbLSiEMXyyW9F6304B_zsDtxpaEgOWftA&_hsmi=143091809&utm_content=142987692&utm_source=hs_email